Health In Tech launches HitRix: AI document intelligence for the $1T self-funded health insurance market

While the AI industry’s attention stays on foundation models and frontier benchmarks, one of the quieter AI plays is happening in insurance paperwork. Health In Tech (Nasdaq: HIT) announced on Thursday the launch of HitRix, an AI-powered platform built to take the administrative grind out of large-group self-funded health insurance submissions — while telling investors the payoff will land in 2027, not this year.

HitRix uses what the company calls AI-powered document intelligence to ingest, extract, organize, and structure case information — census files, claims data, plan documents — cutting the manual data entry and reformatting that consumes brokers’ weeks. Brokers can upload case information in whatever formats they receive it, then manage submissions across multiple carriers and managing general underwriters (MGUs), track market activity in one environment, and compare incoming proposals side by side.

The workflow it is attacking#

For brokers serving larger employers, bringing a case to market is one of the most manual workflows in the industry: collecting volumes of employee census information, claims data, and plan documents; organizing files received in multiple formats; preparing submissions for different carriers and MGUs; tracking responses; and manually comparing proposals.

HitRix is designed to collapse that pipeline into a single environment. The platform’s bet is integration: unlike traditional submission tools focused on document routing or RFP management, HitRix connects submission, market access, analytics, and transaction execution inside Health In Tech’s existing underwriting and marketplace infrastructure.

The numbers attached#

HitRix launches across Health In Tech’s existing distribution network, which stood at 933 partners — brokers, third-party administrators, and agencies — as of June 30, 2026, representing 19.9% year-over-year growth. The company says that base gives the platform a running start, and that each case moving through it builds a growing pool of structured market and placement data to feed future analytics and automation.

Alongside the launch, Health In Tech updated its full-year 2026 revenue outlook to approximately $33 million, roughly in line with 2025. The flat guidance reflects the timing of HitRix commercialization, its Three-Year Rate Stabilization Program, and additional carrier capacity — all of which the company says will become more meaningful growth contributors in 2027 and beyond, as adoption increases and new business goes into effect.

What the CEO is saying#

“The challenge we are solving with HitRix goes far beyond putting an insurance submission online,” said Tim Johnson, Chief Executive Officer of Health In Tech. “Large-group brokers often manage substantial amounts of census data, claims information and plan documents across different formats and systems. HitRix is designed to let AI handle much of that administrative work while giving brokers one environment to organize the case, access multiple markets and compare proposals.”

Johnson added that the goal “is to make it dramatically easier for brokers to shop the market while keeping them at the center of the client relationship,” calling HitRix “an important step toward building a more connected and intelligent marketplace for self-funded health insurance.”

What to watch#

Health In Tech’s framing is honest about the timeline: 2026 is a build year, 2027 is when HitRix is supposed to move the revenue line. The open question is whether AI document intelligence is a strong enough wedge in a market where relationships and distribution still rule. Brokers already sit inside legacy portals and workflows; getting them to route cases through a new environment — however automated — is an adoption battle, not a technology one.

The data flywheel is the longer play. Every submission that flows through HitRix generates structured placement data the company can use to sharpen underwriting, pricing, and analytics — an asset that compounds if adoption does. For a ~$33M-revenue company, that’s a plausible path to punching above its weight. For now, the market gets to grade the thesis in 2027.